Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alvin Shih is Director at Zevra Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Sep 15, 2025, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
As of the latest filing on , Alvin Shih reported holding 20,000 shares of Zevra Therapeutics (ZVRA), worth about $188K at the last close of $9 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 20,000 | 20K direct | $9 | $188K | Sep 12, 2025 |
Is this Alvin Shih’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median +9.4 pts vs S&P 500, beat it 1 of 1 time.
Average +9.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Sep 15, 2025 to Sep 15, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 100% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Sep 12, 2025Bought~$158Kdisclosed Sep 15
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Alvin Shih bought shares on the open market in 2025 across 2 companies. Sales in 2 of the 12 years since 2015.
Alvin Shih reported 1 open-market purchase and 8 sales since 2015; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $158K1×1 trade | — |
| 2016 | — | $423K3×3 trades |
| 2015 | — | $1.27M5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Sep 12, 2025, Alvin Shih reported holding 20,000 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $188K. This is the stake disclosed in filings, not a net worth.
Alvin Shih bought shares on the open market in 2025 across 2 companies. Sales in 2 of the 12 years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2025; the latest open-market sale is from 2016.
2 companies: Zevra Therapeutics (ZVRA, 2025), Travere Therapeutics (TVTX, 2015–2016).
Alvin Shih reported 0 open-market purchases and 8 sales here, 2015 to 2016.
Alvin Shih reported 1 open-market purchase and 0 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.